- Home
- AGEN vs BARK Comparison
AGEN vs BARK Comparison
Compare AGEN & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- BARK
- Stock Information
- Founded
- AGEN 1994
- BARK 2011
- Country
- AGEN United States
- BARK United States
- Employees
- AGEN N/A
- BARK N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BARK Department/Specialty Retail Stores
- Sector
- AGEN Health Care
- BARK Consumer Discretionary
- Exchange
- AGEN Nasdaq
- BARK Nasdaq
- Market Cap
- AGEN 142.8M
- BARK 146.0M
- IPO Year
- AGEN 2000
- BARK N/A
- Fundamental
- Price
- AGEN $4.25
- BARK $0.86
- Analyst Decision
- AGEN Buy
- BARK Strong Buy
- Analyst Count
- AGEN 2
- BARK 3
- Target Price
- AGEN $14.50
- BARK $2.50
- AVG Volume (30 Days)
- AGEN 431.2K
- BARK 840.5K
- Earning Date
- AGEN 11-11-2025
- BARK 11-06-2025
- Dividend Yield
- AGEN N/A
- BARK N/A
- EPS Growth
- AGEN N/A
- BARK N/A
- EPS
- AGEN N/A
- BARK N/A
- Revenue
- AGEN $101,706,000.00
- BARK $470,831,000.00
- Revenue This Year
- AGEN $60.49
- BARK N/A
- Revenue Next Year
- AGEN N/A
- BARK $6.25
- P/E Ratio
- AGEN N/A
- BARK N/A
- Revenue Growth
- AGEN N/A
- BARK N/A
- 52 Week Low
- AGEN $1.38
- BARK $0.77
- 52 Week High
- AGEN $7.34
- BARK $2.56
- Technical
- Relative Strength Index (RSI)
- AGEN 45.64
- BARK 56.48
- Support Level
- AGEN $3.78
- BARK $0.80
- Resistance Level
- AGEN $4.38
- BARK $0.85
- Average True Range (ATR)
- AGEN 0.24
- BARK 0.03
- MACD
- AGEN 0.00
- BARK 0.00
- Stochastic Oscillator
- AGEN 47.55
- BARK 89.70
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.